Novartis

Healthcare

Created in 1996 through the merger of Ciba-Geigy and Sandoz in Basel, Switzerland, Novartis is a global medicines leader developing advanced therapy platforms, cell & gene therapies, and radioligand treatments.

View Official Novartis Careers

Official Novartis Careers Website

Quick Facts

Founded: 1996 (Roots to 1758)
Merger Of: Ciba-Geigy & Sandoz
Headquarters: Basel, Switzerland
Public Ticker: SIX: NOVN / NYSE: NVS

About Novartis

Novartis was created in 1996 through the historic merger of Swiss chemical and pharmaceutical companies Ciba-Geigy and Sandoz. Its roots trace back over 250 years to Geigy (1758), Ciba (1859), and Sandoz (1886) in Basel, Switzerland.

Novartis generates over $45 billion annually as a focused innovative medicines company. Operating across cardiovascular, immunology, neuroscience, solid tumors, and hematology, Novartis leads breakthrough technology platforms including cell and gene therapy (Kymriah), radioligand therapy (Pluvicto), and RNA therapeutics (Leqvio).

What Novartis Does

Cell & Gene Therapy

Pioneering CAR-T therapies (Kymriah) and gene replacement treatments for spinal muscular atrophy (Zolgensma).

Radioligand Therapy (RLT)

Targeted nuclear medicine treatments binding cancer cells directly with therapeutic radiation (Pluvicto, Lutathera).

Cardiovascular & Renal

Heart failure and cholesterol-lowering therapeutics including Entresto and Leqvio (siRNA technology).

Immunology & Neuroscience

Treatments for multiple sclerosis (Kesimpta), psoriasis (Cosentyx), and neurological diseases.

Career Areas

Types of professional roles found inside Novartis.

R&D Discovery & Biomedical Research
Cell & Gene Therapy Engineering
Clinical Trial Development & Operations
Global Technical Operations & Manufacturing
Biostatistics & Healthcare AI
Commercial Strategy & Market Access
Financial Management
Human Resources & Legal

Novartis's History

1996
Ciba-Geigy & Sandoz Merge
Merger of Ciba-Geigy and Sandoz creates Novartis in one of history's largest corporate transactions.
2001
Gleevec Launch
Launches targeted leukemia therapy Gleevec, ushering in modern precision oncology.
2017
First FDA-Approved CAR-T
Kymriah becomes the first FDA-approved CAR-T cell therapy in history.
2022
Pluvicto RLT Approval
Secures approval for Pluvicto, establishing leadership in radioligand prostate cancer therapy.
2023
Sandoz Spin-Off
Spins off generic drug division Sandoz to focus 100% on innovative prescription medicines.